
|Articles|February 15, 2016
FDA Warning to Cannabidiol Suppliers
Author(s)Randi Hernandez
February 15, 2016.
Advertisement
FDA sent out eight warning letters on earlier this month to various makers of a dietary supplement called cannabidiol, which is derived from the Cannabis plant. Cannabidiol, also known as CBD oil, is described as a nonpsychoactive dietary supplement that is purported to have numerous benefits, including anti-inflammatory and antiemetic properties.
However, FDA said the CBD oil products are being marketed as medications and have not been adequately tested to prove they are safe and effective.
See more on this story at Pharmaceutical Technology
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: McKesson to Acquire Precision Medicine Group, Lundbeck & Eversana Enter AI-Powered Partnership
2
Why Integrated GMP Operating Models Are Reshaping Outsourced Manufacturing
3
The Retailization of Medicare Advantage: What Costco’s Entry Means for Pharma
4
Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321
5




